1. Academic Validation
  2. Discovery and structure-activity relationships of a novel oxazolidinone class of bacterial type II topoisomerase inhibitors

Discovery and structure-activity relationships of a novel oxazolidinone class of bacterial type II topoisomerase inhibitors

  • Bioorg Med Chem Lett. 2022 Jun 1:65:128648. doi: 10.1016/j.bmcl.2022.128648.
Amanda Lyons 1 James Kirkham 2 Kevin Blades 2 David Orr 2 Elizabeth Dauncey 1 Oliver Smith 2 Emma Dick 1 Rolf Walker 1 Teresa Matthews 1 Adam Bunt 2 Jonathan Finlayson 1 Ian Morrison 1 Victoria J Savage 2 Emmanuel Moyo 2 Hayley S Butler 1 Rebecca Newman 2 Nicola Ooi 2 Andrew Smith 1 Cédric Charrier 1 Andrew J Ratcliffe 1 Neil R Stokes 1 Stuart Best 1 Anne-Marie Salisbury 1 Mark Craighead 1 Ian R Cooper 3
Affiliations

Affiliations

  • 1 Redx Anti-Infectives Ltd, Alderley Park, Cheshire SK10 4TG, UK.
  • 2 Infex Therapeutics Ltd, Mereside, Alderley Park, Macclesfield SK10 4TG,UK.
  • 3 Infex Therapeutics Ltd, Mereside, Alderley Park, Macclesfield SK10 4TG,UK. Electronic address: ian.cooper@infextx.com.
Abstract

There is an increasingly urgent and unmet medical need for novel Antibiotic drugs that tackle infections caused by multidrug-resistant (MDR) pathogens. Novel Bacterial type II Topoisomerase inhibitors (NBTIs) are of high interest due to limited cross-resistance with fluoroquinolones, however analogues with Gram-negative activity often suffer from hERG channel inhibition. A novel series of bicyclic-oxazolidinone inhibitors of Bacterial type II Topoisomerase were identified which display potent broad-spectrum anti-bacterial activity, including against MDR strains, along with an encouraging in vitro safety profile. In vivo proof of concept was achieved in a A. baumannii mouse thigh Infection model.

Keywords

Anti-infectives; DNA gyrase; ESKAPE pathogens; NBTI; Oxazolidinone; Topoisomerases.

Figures